Author:
Chen Gong,Zhao Xiaofang,Chen Xinglin,Liu Chengyun
Abstract
Abstract
Background
Previous studies have declared that baseline lymphocyte count is associated with COVID-19-related death. However, whether dynamic lymphocyte change over time affects prognosis in COVID-19 patients is unknown. This study aims to investigate the significance of lymphocyte count during the progression of the disease in COVID-19 patients.
Methods
The retrospective cohort study recruited COVID-19 patients at the First People’s Hospital of Jiangxia District in Wuhan from January 7, 2020, to February 28, 2020. The demographics, medical histories, results of the blood routine test, and patients’ outcomes were collected. We utilized a generalized additive mixed model to compare trends in lymphocyte count over time among survivors and non-survivors, with an adjustment for potential confounders. The statistical analysis used R software and EmpowerStats. Significance was determined at a P-value of less than 0.05 (two-sided).
Results
A total of 532 patients were included in the study. Overall, there were 29/532 in-hospital deaths (5.45%). Lymphocytes declined over time in the non-survivor group and increased in the survivor group in the first 10 days of hospitalization. Within 10 days after admission, lymphocyte count increased in the survivor group and decreased in the non-survivor group. The difference in lymphocyte counts between survivors and non-survivors increased by an average of 0.0732 × 109/L daily. After adjusting for several covariables, the increasing value remained at 0.0731 × 109/L per day.
Conclusion
In the early stage, lymphocyte count can dynamically reflect the pathophysiological changes in COVID-19 patients. An early decrease in lymphocyte count is associated with mortality in COVID-19 patients.
Publisher
Springer Science and Business Media LLC
Subject
Pulmonary and Respiratory Medicine
Reference15 articles.
1. Benowitz NL, Goniewicz ML, Halpern-Felsher B, Krishnan-Sarin S, Ling PM, O'Connor RJ, Pentz MA, Robertson RM, Bhatnagar A. Tobacco product use and the risks of SARS-CoV-2 infection and COVID-19: current understanding and recommendations for future research. Lancet Resp Med. 2022;10(9):900–15.
2. Solmi M, Estrade A, Thompson T, Agorastos A, Radua J, Cortese S, Dragioti E, Leisch F, Vancampfort D, Thygesen LC, et al. The collaborative outcomes study on health and functioning during infection times in adults (COH-FIT-adults): design and methods of an international online survey targeting physical and mental health effects of the COVID-19 pandemic. J Affect Disorders. 2022;299:393–407.
3. Mirahmadizadeh A, Maleki Z, Miyar A, Sahebi R, Dadvar A, Moradian MJ, Rastegarfar B, Daliri M, Mohammadi Abnavi M, Ghaem H. Prognosis of COVID-19 infection among opium users in Iran,2020: a hospital-based study. J Subst Use:1–5.
4. Vali M, Mirahmadizadeh A, Maleki Z, Afrashteh S, Abedinzade A, Kasraei F, Ghaem H. Physical and psychological problem of COVID-19 infection in healthcare workers: a systematic review and Meta-analysis. J Health Sci Surveill Syst. 2022;10(3):250–6.
5. Bahardoust M, Heiat M, Khodabandeh M, Karbasi A, Bagheri-Hosseinabadi Z, Ataee MH, Seidalian N, Babazadeh A, Agah S, Abyazi MA. Predictors for the severe coronavirus disease 2019 (COVID-19) infection in patients with underlying liver disease: a retrospective analytical study in Iran. Sci Rep. 2021;11(1):3066.